TapewireFind a company

person · Reporting owner

Grossman Adam S

Disclosed activity across 1 company

Tapewire entity
59867
SEC CIK
0001542517

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADMA BIOLOGICS, INC.ADMA · Entity 4477Director · President and CEOMarch 16, 2026March 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date March 16, 2026 · Filed March 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,133,777 Reported balance After 2026-03-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-03-16 · Exercise / conversion · Acquired 15,000 · Balance 2,133,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Common StockSEC Table I · non-derivativeDirect2,118,777 Reported balance After 2026-03-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-03-16 · Sale · Disposed 15,000 · Balance 2,118,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

Common StockSEC Table I · non-derivativeDirect2,112,777 Reported balance After 2026-03-16 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-03-16 · Sale · Disposed 6,000 · Balance 2,112,777

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2034-02-26Direct690,950 Reported balance After 2026-03-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-03-16 · Exercise / conversion · Disposed 15,000 · Balance 690,950

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Common StockSEC Table I · non-derivativeIndirectSee Footnote1,143,426 Reported balance Holding disclosure · report date 2026-03-16 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 1,143,426

F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

Common StockSEC Table I · non-derivativeIndirectSee Footnote580,957 Reported balance Holding disclosure · report date 2026-03-16 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 580,957

F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2: The price reported in Column 4 is the price at which the shares were sold.

F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 16, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-26-009899 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 690,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $15.16 $90,960.00
Disclosure

SEC source: 0001140361-26-009899 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,112,777

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $15.16 $227,400.00
Disclosure

SEC source: 0001140361-26-009899 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,118,777

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
March 16, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-26-009899 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,133,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Read SEC document
March 07, 2026 Filed Mar 11, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 29,513 $15.39 $454,205.07
Disclosure

SEC source: 0001140361-26-008904 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,118,777

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) and (v) 1,224,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 06, 2026 Filed Mar 11, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 56,438 $15.39 $868,580.82
Disclosure

SEC source: 0001140361-26-008904 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,148,290

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

Read SEC document
February 26, 2026 Filed Mar 3, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 54,858 $15.18 $832,744.44
Disclosure

SEC source: 0001140361-26-007406 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,204,728

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,092,470 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 19, 2026 Filed Feb 24, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 24,793 $16.32 $404,621.76
Disclosure

SEC source: 0001140361-26-006461 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,259,586

F1 · shares: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

F2 · balance_after: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 1,007,896 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 17, 2026 Filed Feb 18, 2026 02:39 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-26-005888 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 705,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
February 17, 2026 Filed Feb 18, 2026 02:39 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $16.08 $96,480.00
Disclosure

SEC source: 0001140361-26-005888 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,284,379

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 17, 2026 Filed Feb 18, 2026 02:39 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $16.08 $241,200.00
Disclosure

SEC source: 0001140361-26-005888 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,290,379

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
February 17, 2026 Filed Feb 18, 2026 02:39 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-26-005888 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,305,379

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.

Read SEC document
February 09, 2026 Filed Feb 12, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 444,711 $0.00 Strike: $16.37 $0.00
Disclosure

SEC source: 0001140361-26-004890 · form4.xml · derivative · entry 4

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 444,711

Underlying: Common Stock · 444,711 shares

Expires 2036-02-09

F7 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.

Read SEC document
February 09, 2026 Filed Feb 12, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 282,529 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-004890 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,290,379

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 975,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-045737 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 720,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $19.79 $118,740.00
Disclosure

SEC source: 0001140361-25-045737 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,007,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 975,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $19.79 $296,850.00
Disclosure

SEC source: 0001140361-25-045737 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,013,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-045737 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,028,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
November 19, 2025 Filed Nov 22, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-042997 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 735,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
November 19, 2025 Filed Nov 22, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $16.00 $96,000.00
Disclosure

SEC source: 0001140361-25-042997 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,013,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 981,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
November 19, 2025 Filed Nov 22, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $16.00 $240,000.00
Disclosure

SEC source: 0001140361-25-042997 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,019,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
November 19, 2025 Filed Nov 22, 2025 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-042997 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,034,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
October 24, 2025 Filed Oct 25, 2025 01:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-039331 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 750,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
October 24, 2025 Filed Oct 25, 2025 01:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $16.00 $96,000.00
Disclosure

SEC source: 0001140361-25-039331 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,019,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 987,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
October 24, 2025 Filed Oct 25, 2025 01:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $16.00 $240,000.00
Disclosure

SEC source: 0001140361-25-039331 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,025,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
October 24, 2025 Filed Oct 25, 2025 01:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-039331 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,040,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-035159 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 765,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $16.13 $96,780.00
Disclosure

SEC source: 0001140361-25-035159 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,025,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 993,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $16.13 $241,950.00
Disclosure

SEC source: 0001140361-25-035159 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,031,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
September 15, 2025 Filed Sep 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-035159 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,046,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
August 15, 2025 Filed Aug 16, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-031601 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 780,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
August 15, 2025 Filed Aug 16, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $16.88 $101,280.00
Disclosure

SEC source: 0001140361-25-031601 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,031,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 999,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 15, 2025 Filed Aug 16, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $16.88 $253,200.00
Disclosure

SEC source: 0001140361-25-031601 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,037,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
August 15, 2025 Filed Aug 16, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-031601 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,052,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
July 15, 2025 Filed Jul 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-026099 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 795,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
July 15, 2025 Filed Jul 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $18.66 $111,960.00
Disclosure

SEC source: 0001140361-25-026099 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,037,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,005,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
July 15, 2025 Filed Jul 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $18.66 $279,900.00
Disclosure

SEC source: 0001140361-25-026099 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,043,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
July 15, 2025 Filed Jul 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-026099 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,058,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-023017 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 810,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $20.81 $124,860.00
Disclosure

SEC source: 0001140361-25-023017 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,043,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,011,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $20.81 $312,150.00
Disclosure

SEC source: 0001140361-25-023017 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,049,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-023017 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,064,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
May 15, 2025 Filed May 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-019589 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 825,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
May 15, 2025 Filed May 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $19.45 $116,700.00
Disclosure

SEC source: 0001140361-25-019589 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,049,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,017,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
May 15, 2025 Filed May 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $19.45 $291,750.00
Disclosure

SEC source: 0001140361-25-019589 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,055,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
May 15, 2025 Filed May 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-019589 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,070,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document
April 15, 2025 Filed Apr 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-25-014267 · form4.xml · derivative · entry 6

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 840,950

Underlying: Common Stock · 15,000 shares

Expires 2034-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F8 · derivative.exercise_date: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.

Read SEC document
April 15, 2025 Filed Apr 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 6,000 $21.46 $128,760.00
Disclosure

SEC source: 0001140361-25-014267 · form4.xml · nonDerivative · entry 3

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,055,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

F3 · balance_after: Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,023,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
April 15, 2025 Filed Apr 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 15,000 $21.46 $321,900.00
Disclosure

SEC source: 0001140361-25-014267 · form4.xml · nonDerivative · entry 2

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,061,850

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

F2 · price: The price reported in Column 4 is the price at which the shares were sold.

Read SEC document
April 15, 2025 Filed Apr 17, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 15,000 $5.40 $81,000.00
Disclosure

SEC source: 0001140361-25-014267 · form4.xml · nonDerivative · entry 1

Grossman Adam S · CIK 0001542517 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,076,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.